- Produced for Pacira by BBC StoryWorks Commercial Productions, The Next Frontier: Mark & Leah’s Story Highlights the Impact of Non-Opioid Solutions - BRISBANE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the debut of a powerful new film spotlighting the journey of a couple who, after navigating the complexities of acute and chronic pain—and ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Pacira BioSciences, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors following a significant patent ruling that negatively impacted the company's stock value [1][2]. Summary by Relevant Sections Company Overview - Pacira BioSciences, Inc. is primarily known for its product Exparel, which constitutes approximately 80% of its revenue [2]. Legal Issues - A class action complaint was filed against Pacira on June 16, 2025, concerning a Class Period from August 2, 2023, to August 8, 2024, focusing on potential breaches of fiduciary duties by the company's board [1]. - On August 9, 2024, Pacira announced that its U.S. Patent No. 11,033,495 was deemed invalid by the court, which raises concerns about the validity of its other patents and could lead to increased competition from generic products [2]. Stock Performance - Following the announcement regarding the patent ruling, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [3].

-- PCRX-201 demonstrated sustained clinical efficacy with improvements in pain, stiffness, and function for up to three years – BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced new long-term follow-up data from its Phase 1 clinical trial evaluating PCRX-201 (enekinragene inzadenovec), a novel gene therapy candidate for osteoarthritis of ...

Pacira BioSciences Inc (PCRX) 2025 Conference June 04, 2025 08:45 AM ET Speaker0 Hi, good morning. Welcome to the Jefferies Healthcare Conference in New York, day one. My name is Dennis Singh, biotech analyst here at Jefferies. I have the pleasure of having Paseer Biosciences CEO, Frank Lee, here with us. Welcome. Frank, maybe to kind of kick things off, just give a brief overview of the company for those who aren't familiar. Just talk about the business and, you know, how things have evolved over the last ...

Pacira BioSciences Inc (PCRX) 2025 Conference May 21, 2025 08:30 AM ET Speaker0 Welcome back everyone to the twenty twenty five RBC Global Healthcare Conference. My name is Greg Renza, one of the biotech analysts, and we're pleased to be joined now by Pacira Biosciences. Joining us from the company is the Chief Executive Officer, Frank Lee. Frank, great to see you. Thanks for being here. Speaker1 Good to see you, Greg. Yeah. Happy to be here. Speaker0 Great. Great. Well, always a lot going on in the externa ...

No serious treatment-emergent AEs related to the treatment or procedure were reported regardless of steroid pretreatment or dose level administered. Treatment-related joint effusions (swelling) were the most common AE, occurring in 36% of patients who received steroid pretreatment vs 61% of patients who were not pretreated. The majority of effusions were mild to moderate in severity and resolved in a median of 33 days among patients in the pretreated group. -- Early clinical data indicates that Pre-existing ...

SAN DIEGO, May 13, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX).Investors who purchased shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) prior to August 2023 and continue to hold any of thoseNASDAQ: PCRX shares also have certain options and contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.On January 13, 2025, aNASDAQ: PCRX investor filed a lawsuit against P ...

1Q25 Earnings PCRX | May 2025 Forward-looking statements and where to find additional information Any statements in this presentation about Pacira's future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words "believes," "anticipates," "plans," "estimates," "expects," "intends," "may," "will," "would," "could," "can" and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as ...

Pacira BioSciences (PCRX) reported first-quarter 2025 adjusted earnings of 62 cents per share, which beat the Zacks Consensus Estimate of 57 cents. The company had also reported adjusted earnings of 62 cents per share in the year-ago quarter.Total revenues amounted to $168.9 million, which increased 1% year over year. The reported figure, however, missed the Zacks Consensus Estimateof $175million. (See the Zacks Earnings Calendar to stay ahead of market-making news.)PCRX’s Q1 Results in DetailPacira BioScie ...

Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Susan Mesco - Vice President Investor RelationsFrank Lee - CEO & DirectorJonathan Slonin - Chief Medical OfficerShawn Cross - Chief Financial OfficerAnish Nikhanj - Senior Associate - Biotechnology Equity ResearchBrendan Teehan - Chief Commercial OfficerGary Nachman - Managing Director - Equity ResearchJeevan Larson - Equity Research Associate Conference Call Participants Hardik Parikh - Equity Research Analyst ...